Hyperlipidemia is protective against cancer comorbidities : But statins may the reason!! -Abstract submitted at BCS 2016 [OMG!!]

A research abstract accepted by British Cardiovascular Society (BCS) for BCS conference 2016, shows the “real quality of research and conference.”


Conclusion: We have demonstrated for the first time that comorbid hyperlipidaemia has a highly protective effect on mortality amongst patients with the four most prevalent cancers in the UK. The underlying reasons for this are yet to be determined but treatment with statins may contribute. This potentially beneficial effect of lipid-lowering medications amongst cancer patients should be further investigated.”

Courtesy: Dr. Anand Srinivasan – “Whole world would appreciate if a famous group provides a conclusion like this. But the author has gone over board in including statin in the conclusion.”


For more information please read the abstract submitted to BCS.

Watch Full Movie Online Streaming Online and Download


During a discussion, two perspectives about the result and title of the article surfaced.
1) If hypercholesterolemia is protective in cancer patients, how can you attribute this to statin?
2) Hypercholesterolemia is protective in cancer patients and this is just an observation which can be attributed statin intake for hypercholesterolemia. Thereby they have mentioned the same in their title.

Similar observation of the blood glucose and HbA1c levels in diabetic patients with gastritis who were on Proton Pump Inhibitors (PPIs), showed that PPIs have hypoglycemic effect and the mechanism were multiple. But PPIs can be given as an anti-diabetic drug because PPIs have not shown Cardio-vascular (CV) benefits on chronic use. And after chronic use, the risk outweighed the benefit.
So according to US-FDA guidelines, If a drug is not able to show CV benefit in diabetes patients, it shouldn’t be prescribed ahead of a drug which has shown CV benefits in such patients.

IMPAS thanks Dr. Maulik Doshi, Dr. Anand Srinivasan , Dr. Shyam Balaji and all others who participated in this discussion.

Drugs<>Therapeutics<>Big Pharma
impas Natesh Prabhu Administrator & Chief Editor | Clinical Pharmacologist | Diabetic-Sexual Medicine-Regenerative Therapy Consultant | President, Indian Medical Pharmacologists Association